000K  utf8
1100  $c2015
1500  eng
2050  urn:nbn:de:gbv:8-publ-23538
2051  10.3389/fneur.2015.00216
3000  Reijs, Babette L. R.
3010  Baldeiras, Inês
3010  Betsou, Fay
3010  Blennow, Kaj
3010  Brosseron, Frederic
3010  Cavedo, Enrica
3010  de Mendonça, Alexandre
3010  Fladby, Tormod
3010  Froelich, Lutz
3010  Gabryelewicz, Tomasz
3010  Goncharenko, Nikolai
3010  Gurvit, Hakan
3010  Kapaki, Elisabeth
3010  Koson, Peter
3010  Kulic, Luka
3010  Lehmann, Sylvain
3010  Lewczuk, Piotr
3010  Lleó, Alberto
3010  Mätzler, Walter
3010  Miller, Anne-Marie
3010  Molinuevo, José L.
3010  Mollenhauer, Brit
3010  Parnetti, Lucilla
3010  Rot, Uros
3010  Scheltens, Philip
3010  Schneider, Anja
3010  Simonsen, Anja Hviid
3010  Tagliavini, Fabrizio
3010  Teunissen, Charlotte E.
3010  Tsolaki, Magda
3010  Verbeek, Marcel M.
3010  Verhey, Frans R. J.
3010  Visser, Pieter Jelle
3010  Winblad, Bengt
3010  Zboch, Marzena
3010  Zetterberg, Henrik
4000  The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases  [Reijs, Babette L. R.]
4209  Biobanks are important resources for biomarker discovery and assay development. Biomarkers for Alzheimer's and Parkinson's disease (BIOMARKAPD) is a European multicenter study, funded by the EU Joint Programme-Neurodegenerative Disease Research, which aims to improve the clinical use of body fluid markers for the diagnosis and prognosis of Alzheimer's disease (AD) and Parkinson's disease (PD). The objective was to standardize the assessment of existing assays and to validate novel fluid biomarkers for AD and PD. To support the validation of novel biomarkers and assays, a central and a virtual biobank for body fluids and associated data from subjects with neurodegenerative diseases have been established. In the central biobank, cerebrospinal fluid (CSF) and blood samples were collected according to the BIOMARKAPD standardized pre-analytical procedures and stored at Integrated BioBank of Luxembourg. The virtual biobank provides an overview of available CSF, plasma, serum, and DNA samples at each site. Currently, at the central biobank of BIOMARKAPD samples are available from over 400 subjects with normal cognition, mild cognitive impairment (MCI), AD, frontotemporal dementia (FTD), vascular dementia, multiple system atrophy, progressive supranuclear palsy, PD, PD with dementia, and dementia with Lewy bodies. The virtual biobank contains information on over 8,600 subjects with varying diagnoses from 21 local biobanks. A website has been launched to enable sample requests from the central biobank and virtual biobank.
4950  https://doi.org/10.3389/fneur.2015.00216$xR$3Volltext$534
4950  https://nbn-resolving.org/urn:nbn:de:gbv:8-publ-23538$xR$3Volltext$534
4961  https://macau.uni-kiel.de/receive/publ_mods_00002353
5051  610
5550  Alzheimer's disease
5550  biobank
5550  body fluids
5550  cerebrospinal fluid
5550  dementia
5550  neurodegenerative disorders
5550  Parkinson's disease